Skip to main content
main-content

John Wilding

John Wilding, DM FRCP, leads Clinical Research into Obesity, Diabetes and Endocrinology at the University of Liverpool, UK. He trained in medicine in Southampton and at the Hammersmith Hospital, London, where he also undertook three years laboratory-based research into the neurobiology of obesity and diabetes. He has worked at University Hospital Aintree, Liverpool, since 1996 and as Professor of Medicine since 2005. He leads specialist services for severe obesity at University Hospital Aintree – designated a Centre for Obesity Management by the European Association for the Study of Obesity. He is a Council member of the Royal College of Physicians and chairs the UK National Clinical Research Network Metabolic and Endocrine Speciality Group. He has published over 250 research papers, chapters and review articles related to his clinical and laboratory research interests in the pathophysiology of obesity and type 2 diabetes and evaluation of new treatments. When not at work he likes to swim, bike and run and completed his first ‘Iron distance’ triathlon in 2015.

Latest contributions from John Wilding

03-06-2019 | Diet | Video | Article

Expert commentary: The 2-year DiRECT outcomes

John Wilding discusses the implications of the 2-year outcomes of the DiRECT trial, and the questions that remain unanswered (4:17).

03-01-2019 | Retinopathy | Video | Article

Diabetic retinopathy: Treatment

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss the treatment of sight-threatening retinopathy and maculopathy in people with diabetes (9:11).

03-01-2019 | Retinopathy | Video | Article

Diabetic retinopathy: Pathogenesis

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss the disease processes that lead to retinopathy in people with diabetes (9:11).

03-01-2019 | Retinopathy | Video | Article

Diabetic retinopathy: Screening

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss diabetic retinopathy screening and the key role that it plays in reducing vision loss among people with diabetes (10:00).

image credits